LNTH Quote, Financials, Valuation and Earnings

Electromed has a net margin of 19.57% compared to Lantheus Holdings's net margin of 12.06%. Lantheus Holdings's return on equity of 23.53% beat Electromed's return on equity of 16.57%.

Lantheus Holdings has a consensus price target of $129.31, signalling upside risk potential of 55.38%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 86.68%. Given that Electromed has higher upside potential than Lantheus Holdings, analysts believe Electromed is more attractive than Lantheus Holdings.

Lantheus Holdings has a beta of 0.106, which suggesting that the stock is 89.373% less volatile than S&P 500. In comparison Electromed has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.159%.

Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Lantheus Holdings quarterly revenues are $372.8M, which are larger than Electromed quarterly revenues of $15.7M. Lantheus Holdings's net income of $72.9M is higher than Electromed's net income of $1.9M. Notably, Lantheus Holdings's price-to-earnings ratio is 23.64x while Electromed's PE ratio is 25.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 3.90x versus 2.89x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Hologic has a net margin of 19.57% compared to Lantheus Holdings's net margin of -1.73%. Lantheus Holdings's return on equity of 23.53% beat Hologic's return on equity of 11.45%.

Lantheus Holdings has a consensus price target of $129.31, signalling upside risk potential of 55.38%. On the other hand Hologic has an analysts' consensus of $67.27 which suggests that it could grow by 4.19%. Given that Lantheus Holdings has higher upside potential than Hologic, analysts believe Lantheus Holdings is more attractive than Hologic.

Lantheus Holdings has a beta of 0.106, which suggesting that the stock is 89.373% less volatile than S&P 500. In comparison Hologic has a beta of 0.549, suggesting its less volatile than the S&P 500 by 45.069%.

Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hologic offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. Hologic pays out -- of its earnings as a dividend.

Lantheus Holdings quarterly revenues are $372.8M, which are smaller than Hologic quarterly revenues of $1B. Lantheus Holdings's net income of $72.9M is higher than Hologic's net income of -$17.4M. Notably, Lantheus Holdings's price-to-earnings ratio is 23.64x while Hologic's PE ratio is 27.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 3.90x versus 3.73x for Hologic. Usually stocks with elevated PS ratios are considered overvalued.

Integra Lifesciences Holdings has a net margin of 19.57% compared to Lantheus Holdings's net margin of -6.61%. Lantheus Holdings's return on equity of 23.53% beat Integra Lifesciences Holdings's return on equity of -1.88%.

Lantheus Holdings has a consensus price target of $129.31, signalling upside risk potential of 55.38%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $16.13 which suggests that it could grow by 16.17%. Given that Lantheus Holdings has higher upside potential than Integra Lifesciences Holdings, analysts believe Lantheus Holdings is more attractive than Integra Lifesciences Holdings.

Lantheus Holdings has a beta of 0.106, which suggesting that the stock is 89.373% less volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.164, suggesting its more volatile than the S&P 500 by 16.396%.

Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend.

Lantheus Holdings quarterly revenues are $372.8M, which are smaller than Integra Lifesciences Holdings quarterly revenues of $382.7M. Lantheus Holdings's net income of $72.9M is higher than Integra Lifesciences Holdings's net income of -$25.3M. Notably, Lantheus Holdings's price-to-earnings ratio is 23.64x while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 3.90x versus 0.66x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of 19.57% compared to Lantheus Holdings's net margin of 0.18%. Lantheus Holdings's return on equity of 23.53% beat Xtant Medical Holdings's return on equity of -26.62%.

Lantheus Holdings has a consensus price target of $129.31, signalling upside risk potential of 55.38%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 161.19%. Given that Xtant Medical Holdings has higher upside potential than Lantheus Holdings, analysts believe Xtant Medical Holdings is more attractive than Lantheus Holdings.

Lantheus Holdings has a beta of 0.106, which suggesting that the stock is 89.373% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.181, suggesting its less volatile than the S&P 500 by 118.091%.

Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Lantheus Holdings quarterly revenues are $372.8M, which are larger than Xtant Medical Holdings quarterly revenues of $32.9M. Lantheus Holdings's net income of $72.9M is higher than Xtant Medical Holdings's net income of $58K. Notably, Lantheus Holdings's price-to-earnings ratio is 23.64x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 3.90x versus 0.75x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.